You are about to leave jnjmedtech.com. By clicking to continue, you will be taken to a web site governed by their own Legal and Privacy Policies.
Health Economics & Market Access
AF Burden of Disease and Treatment
Health Economics & Market Access
AF Burden of Disease and Treatment
As a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, Biosense Webster, Inc. is committed to patient advocacy and raising awareness of atrial fibrillation and its available treatment options.
Atrial fibrillation is a chronic and typically progressive disease that significantly impairs patient quality of life and increases their risk of developing co-morbidities.2
AF increases a patient’s risk of life-threatening complications, such as stroke, heart attack, and heart failure.2 Patients with AF have a 46% higher risk of mortality than individuals without AF.2,3
MEDIA
As a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, Biosense Webster, Inc. is committed to patient advocacy and raising awareness of atrial fibrillation and its available treatment options.
Atrial fibrillation is a chronic and typically progressive disease that significantly impairs patient quality of life and increases their risk of developing co-morbidities.2
AF increases a patient’s risk of life-threatening complications, such as stroke, heart attack, and heart failure.2 Patients with AF have a 46% higher risk of mortality than individuals without AF.2,3